文献速递脊柱关节炎

银屑病关节炎中的医疗保健差异:来自13个国家439例患者的分析

Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries.
PubMed 文献 · RMD Open · 2022-01-01

该横断面研究分析了13个国家439例明确银屑病关节炎(PsA)患者,按人均国内生产总值(GDP)三分位分组比较疾病活动度、影响和治疗。结果显示人均GDP最低三分位国家的患者DAPSA缓解率和MDA达标率更低,疾病活动度和影响更高,而生物制剂使用率三组相似。

要点

  • 人均GDP最低三分位国家DAPSA缓解率7.0%、MDA达标率18.4%,均低于中三分位(29.1%、49.5%)和高三分位(16.8%、41.3%),P<0.001。
  • 三组生物制剂使用率相似,总体平均61%。
  • DAPSA>14且未使用生物制剂的患者总体占18.5%,在人均GDP较低国家更高(P=0.004)。

核心结论

  • 人均GDP最低国家的PsA患者尽管生物制剂使用率相似,更可能出现高疾病活动度和更差的疾病影响,需要更公平的医疗保健。

研究设计与样本

  • 对缓解/复发 in PsA研究(NCT03119805)中13个国家的连续成年明确PsA患者进行横断面分析,国家按人均GDP三分位分类,采用参数和非参数检验比较三组。

主要发现

  • 439例患者中男性50.6%,平均年龄52.3岁,平均病程10.1年,疾病活动度和疾病影响在人均GDP最低国家更高。
  • 人均GDP最低三分位DAPSA缓解率7.0%、MDA达标率18.4%,中三分位分别为29.1%和49.5%,高三分位分别为16.8%和41.3%(均P<0.001)。
  • 生物制剂使用率三组相似,总体平均61%。
  • DAPSA>14且未使用生物制剂的患者总体占18.5%,在人均GDP较低国家更高(P=0.004)。

关键数值与推荐

  • 人均GDP最低三分位DAPSA缓解率7.0%、MDA达标率18.4%,中三分位DAPSA缓解率29.1%、MDA达标率49.5%,高三分位DAPSA缓解率16.8%、MDA达标率41.3%(均P<0.001)。
  • 生物制剂使用率三组相似,总体平均61%。
  • DAPSA>14且未使用生物制剂的患者总体占18.5%,在人均GDP较低国家更高(P=0.004)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patient care can vary substantially by country. The objective was to explore differences in psoriatic arthritis (PsA) across countries for disease activity, impact and treatments. METHODS: A cross-sectional analysis of 13 countries from the Remission/Flare in PsA study (NCT03119805) of consecutive adult patients with definite PsA was performed. Countries were classified into tertiles by gross domestic product (GDP)/capita. Disease activity (Disease Activity in PsA, DAPSA and Minimal Disease Activity, MDA) and their components, disease impact (patient-reported outcomes) and biological disease-modifying antirheumatic drugs (bDMARDs) were analysed per country and compared between the three tertiles of GDP/capita by parametric and non-parametric tests. We also explored the percentage of patients with significant disease activity (DAPSA >14) and no ongoing bDMARD prescription. RESULTS: In 439 patients (50.6% male, mean age 52.3 years, mean disease duration 10.1 years), disease activity and disease impact were higher in the lowest GDP/capita countries. DAPSA remission and MDA were attained in the lowest tertile in 7.0% and 18.4% patients, vs 29.1% and 49.5% in the middle tertile and 16.8% and 41.3% in the high tertile, respectively (all p<0.001). bDMARDs use was similar in the tertiles (overall mean 61%). The overall rate of patients with DAPSA >14 and no bDMARDs was 18.5%, and was higher in lower GDP/capita countries (p=0.004). CONCLUSION: PsA patients from countries with the lowest GDP/capita, despite similar use of bDMARDs, were more likely to have high disease activity and worse disease impact. There is a need for more equity in healthcare.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Lucasson F, Kiltz U, Kalyoncu U, et al. Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. RMD Open. 2022. PMID: 35523519. doi:10.1136/rmdopen-2021-002031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。